{
    "clinical_study": {
        "@rank": "57285", 
        "arm_group": [
            {
                "arm_group_label": "Tenofovir DF", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants received tenofovir DF 300 mg for 14 days"
            }, 
            {
                "arm_group_label": "Tenofovir alafenamide 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants received tenofovir alafenamide 50 mg for 14 days"
            }, 
            {
                "arm_group_label": "Tenofovir alafenamide 150 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants received tenofovir alafenamide 150 mg for 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate\n      (tenofovir DF)."
        }, 
        "brief_title": "A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients", 
        "completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  HIV-1 RNA levels greater than or equal to 30,000 copies/mL\n\n          -  CD4 count greater than or equal to 200 cells/mm3\n\n          -  Serum creatinine <1.5 mg/dl\n\n          -  Hepatic transaminases less than or equal to 2.5 times the upper limit of normal\n\n          -  Total bilirubin less than or equal to 1.5 mg/dL\n\n          -  Adequate hematologic function\n\n          -  Serum amylase less than or equal to 1.5 times the upper limit of normal\n\n          -  Serum phosphate greater than or equal to 2.2 mg/dL\n\n          -  Not pregnant\n\n        Exclusion Criteria\n\n          -  Prior treatment with antiretroviral therapy\n\n          -  Immunization within 30 days  of study entry\n\n          -  A new AIDS defining condition within 30 days of study entry\n\n          -  Receiving nephrotoxic agents, probenecid,  chemotherapeutic agents, corticosteroids,\n             interleukin-2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 13, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00036634", 
            "org_study_id": "GS-120-1101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tenofovir DF", 
                "description": "Tenofovir DF tablet administered orally once daily", 
                "intervention_name": "Tenofovir DF", 
                "intervention_type": "Drug", 
                "other_name": "Viread\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Tenofovir alafenamide 50 mg", 
                    "Tenofovir alafenamide 150 mg"
                ], 
                "description": "Tenofovir alafenamide tablet(s) administered orally once daily", 
                "intervention_name": "Tenofovir alafenamide", 
                "intervention_type": "Drug", 
                "other_name": "GS-7340"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tenofovir", 
                "Tenofovir disoproxil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "treatment naive", 
        "lastchanged_date": "January 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94304"
                    }, 
                    "name": "Stanford Positive Care Program"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60610"
                    }, 
                    "name": "Protocare Trials Chicago Center for Clinical Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Rockefeller University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1/2, Randomized, Double-Blind, Active Controlled, Dose Escalation Study of the Safety, Tolerance, Pharmacokinetic,, and Antiviral Activity of GS-7340-02 in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "DAVG2 was defined as the time-weighted average between baseline value through the last available value up to week 2 minus the baseline value.", 
            "measure": "Time-weighted average change from baseline through Week 2 (DAVG2) for HIV-1 RNA (log10 copies/mL)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00036634"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in HIV-1 RNA (log10 copies/mL)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 2"
            }, 
            {
                "measure": "Change from baseline in CD4 cell count (cells/mm3)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 2"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }, 
    "geocoordinates": {
        "Protocare Trials Chicago Center for Clinical Trials": "41.878 -87.63", 
        "Rockefeller University Hospital": "40.714 -74.006", 
        "Stanford Positive Care Program": "37.442 -122.143"
    }
}